

1. Title page

European Journal of Cardio-Thoracic Surgery

Cost and survival of video-assisted thoracoscopic lobectomy vs. open lobectomy in lung cancer patients: a propensity score-matched study

Pavo Marijic^{1,2}, Julia Walter^{2,4}, Christian Schneider^{3,4}, Larissa Schwarzkopf^{2,4}

¹Ludwig-Maximilians-Universität München, Institute for Medical Information Processing, Biometry and Epidemiology (IBE), Munich, Germany

²Helmholtz Zentrum München, Institute of Health Economics and Health Care Management (IGM), Munich, Germany

³Ludwig-Maximilians-Universität München, Department of Thoracic Surgery, Munich, Germany

⁴Comprehensive Pneumology Center Munich (CPC-M), member of the German Center for Lung Research (DZL)

Word count (overall): 5031

Pavo Marijic
Institute of Health Economics and Health Care Management (IGM)
Helmholtz Zentrum München
Ingolstädter Landstraße 1, 85764 Neuherberg, Bavaria, Germany
Tel: +49-89-318743551
E-mail: pavo.marijic@helmholtz-muenchen.de

37 Key question: Is VATS superior or equal to OT regarding survival, cost and length of hospital
38 stay?

39

40 Key findings: No difference in survival & Costs for hospital stay are similar between methods,
41 but lung cancer-related costs are lower & Length of hospital stay is shorter in VATS

42

43 Take-home message: VATS shows advantages in length of hospital stay and is at least
44 equal in costs and three-year survival in comparison to OT.

2. Abstract

Objectives: Video-assisted thoracoscopic surgery (VATS) is an accepted alternative to open thoracotomy (OT) in lung cancer patients undergoing lobectomy, but evidence for the benefits of VATS remains inconsistent. The aim of this study was to compare VATS and OT regarding survival, costs and length of hospital stay (LOS).

Methods: We identified lung cancer patients (incident 2013) undergoing VATS or OT from German insurance claims data and performed 1:2 propensity score matching (PSM). Three-year survival was analysed using Kaplan-Meier curves and a univariable Cox model. Group differences in three-year lung cancer-related costs and costs of hospital stay with lobectomy were compared via univariable generalized linear gamma models. LOS was compared using a Mann-Whitney-Wilcoxon Test.

Results: After PSM we compared 294 patients undergoing VATS and 588 receiving OT. We found no differences in 3-year survival (VATS: 73.8%, OT: 69.2%, $p=0.131$) or costs for hospital stay with lobectomy (VATS: €11,921, OT: €12,281, $p=0.573$). However, VATS patients had significantly lower lung cancer-related costs (VATS: €20,828, OT: €23,723, $p=0.028$) and median postoperative LOS (VATS: 9 days, OT: 11 days, $p<0.001$).

Conclusions: Adopting a payer perspective, extending the use of VATS is beneficial, as it shows economic benefits without differing survival. However, for a more comprehensive assessment of the benefits of VATS from a societal point of view, further aspects such as patient-reported outcomes and provider-related standby costs need to be investigated further.

Keywords: Video-Assisted Thoracic Surgery • Open Thoracotomy • Lung Cancer • Spending • Mortality • Length of Stay

3. Introduction

Among all types of cancer, lung cancer has the highest incidence worldwide and is the most common cause of cancer death [1]. When curative treatment intent is possible, a lobectomy is the recommended procedure. Lobectomy can be performed as either an open thoracotomy (OT) or video-assisted thoracoscopic surgery (VATS), and there are no clear recommendations about the method that should be used. Owing to progress in the last 20 years, VATS has become an accepted alternative to open thoracotomy (OT) and has been used increasingly [2].

Some studies have reported advantages in post-operative length of hospital stay (LOS), overall complications [3], quality of life and postoperative pain [4] for patients undergoing VATS, but evidence on survival benefits is inconsistent [5, 6]. This is also true for the economic implication of VATS compared with OT [7, 8]. Comprehensive comparisons on the costs and effects of VATS and OT are still sparse, particularly for the time period beyond the hospital stay for lobectomy.

The intention of this study was to provide patient-level information comparing VATS and OT using data from a large health insurance company.

The primary aim is to compare survival up to 3-years between VATS and OT as well as 3-year lung cancer-related costs. The secondary aim is to investigate cost differences in the costs of hospital stay with lobectomy and differences in post-operative LOS after lobectomy.

4. Materials and methods

Study design

Data set

The primary data set contained 18,770 patients diagnosed with lung cancer in 2013 provided by the AOK research institute (WIdO). In Germany, health insurance is mandatory and, in 2013, the AOK Statutory Health Insurance Funds (SHI) covered around one third of the resident German population [9].

The data set contained information on claims for hospitalizations, outpatient hospital visits, outpatient physician visits and drug prescriptions including OPS (German version of the International Classification of Procedures in Medicine), ATC (German Anatomical Therapeutic Chemical Classification) and ICD-10 (International Classification of Diseases, German Modification) codes. Available patient-level information were month and year of birth and death (where applicable), sex, nursing home residency, care level and residential area through postal codes. We had information about each individual patient over a 3-year follow-up period after diagnosis.

Sample selection

We identified patients with incident lung cancer according to a three-step process. First, we selected all patients with a diagnosis of lung cancer (ICD-10 code C34) in 2013. In a second step, to avoid false positives, we only included patients with at least one inpatient principal diagnosis or at least two confirmed outpatient diagnoses in two distinct quarters in 2013. Third, we excluded all patients with a history of lung cancer or lung metastases in the 2 years prior to 2013, as well as patients without continuous insurance in these years.

We included all patients undergoing a lobectomy in the first 365 days after diagnosis based on the corresponding OPS codes (OPS 5.324). We excluded all patients with a code for VATS as well as OT on the same day, a larger resection than lobectomy, a robotic-assisted surgery, an aborted surgery or a code for lobectomy as a reoperation. The first lobectomy after diagnosis was used for assignment to the VATS or OT group, regardless of further procedures.

Group assignment

The main variable of interest in this study was whether lobectomy was performed as VATS or OT. We identified both groups by looking at the OPS codes (VATS 5324.7, 5324.8 | OT 5324.A, 5324.B) from the day of the lobectomy.

Outcome variables

Our primary outcomes were survival and costs of care over a 3-year time frame.

We calculated survival as the time between date of diagnosis up a maximum of 3 years.

Patients with longer survival were censored at 3 years.

We calculated lung cancer-related costs as costs of hospitalizations with a primary diagnosis of lung cancer, costs of lung cancer-related drugs (chemotherapeutics, inhibitors, immunotherapeutics, antiemetics, antianaemics, bisphosphonates and granulocyte-colony stimulating factors) and outpatient physician visits with a confirmed diagnosis of lung cancer. [Outpatient ICD diagnoses in Germany have to be categorized as: 'Z'=condition after, 'A'=exclusion diagnosis, 'V'=suspected diagnosis and 'G'=confirmed diagnosis.]

Secondary outcomes were costs of the hospital stay with lobectomy and post-operative LOS after lobectomy. In order not to introduce bias, we added the post-operative LOS and costs of subsequent hospital stays if a patient was transferred to another hospital after lobectomy. Costs of the hospital stay with lobectomy as well as lung cancer-related costs refer to costs for the health insurance company, without accounting for additional costs, e.g. material costs for the hospital, over-the-counter drugs or any other cost that was paid by the patient.

Variables used for Propensity Score Matching

We used propensity score matching (PSM) to balance the distributions of potential confounders for patients treated by VATS or OT.

The variables used to estimate the PS were age, sex, metastasis status, Charlson Comorbidity Index, care level, nursing home residency, neoadjuvant chemotherapy, neoadjuvant radiotherapy, number of lobectomies per hospital, days from admission to surgery and residential area. We assessed metastasis status as ICD-10 codes, coded in the quarter before and after diagnosis and categorized them as no metastases, lymph node metastases (ICD-10 code C77) and other metastases (ICD-10 codes C78, C79). To calculate the Charlson comorbidity index at baseline we included the ICD-10 codes for the 2 years prior to diagnosis. Lung cancer was excluded from this calculation to only account for additional primary tumours given the presence of lung cancer. Carelevel was defined as the need for long-term care and was coded as a binary variable. Nursing home residency was available as a binary variable, defining whether a patient lived in a nursing home. Neoadjuvant chemotherapy and neoadjuvant radiotherapy referred to chemotherapy and radiotherapy between the date of diagnosis and the date of lobectomy and were identified via OPS, ATC and GONR (German

medical fee index) codes. We identified patients treated in the same hospital using an anonymized hospital reference number. From this, we calculated the number of lobectomies per hospital. Number of days between admission and surgery was defined as days from hospital admission to lobectomy. We classified residential area as major city, urban districts, rural districts and remote rural districts using the zip code-based definition of district types defined by the Federal Institute for Research on Building, Urban Affairs and Spatial Development [10].

Propensity Score Matching

We used nearest neighbor matching as the matching algorithm. Matching was done without replacement. A maximal possible difference, the caliper width, between matched subjects was pre-specified at 0.2 standard deviations of the logit of the PS, as suggested by Austin in 2011 [11]. The balance of the PS between the groups was assessed by the standardized mean difference (SMD), which was compared before and after matching. Differences of less than 0.1 were considered as to be well matched [12]. As the number of patients in the OT group was much higher, we matched two OT patients to one VATS patient. Two to one matching was found to perform better in the context of the bias-variance trade-off in comparison with choosing three or more controls [13]. When analyzing the data, the whole groups were used and the matched pairs were treated as independent [14].

Statistical Analysis/Methods

When PSM is performed, a direct treatment effect can be estimated between the groups within the matched sample [12]. Therefore, no additional confounder adjustment is needed when analysing the matched sample.

Kaplan-Meier curves were used to describe the survival over 3 years and compared using log-rank tests. We used a univariable Cox proportional hazard model to calculate the hazard ratio (HR) between VATS and OT and the 95% confidence intervals (CIs). To test the cost-specific group differences in total costs and for each cost category, univariable generalized linear gamma models [15, 16] with a log link were used.

To test the differences in post-operative LOS, a Mann-Whitney-Wilcoxon Test was performed.

For this analysis, patients who died during the hospital stay with lobectomy were excluded.

In a sensitivity analysis, we analysed costs for survivors only, as the costs for patients who died were much higher, which could lead to differences in costs caused by a small number of patients. Therefore, we examined an additional PSM. The procedure for this PSM was the same as described above.

All tests were two-sided and were defined as significant at $p \leq 0.05$. All analyses were done with R-Software 3.4.2.

5. Results

Sample selection

Of the 18,770 lung cancer patients 1,884 (10.3%) underwent lobectomy within 365 days after the initial diagnosis. From this sample, we excluded 125 patients in accordance with our eligibility criteria. The final sample consisted of 1,759 patients, of whom 1,465 (83.3%) had OT and 294 (16.7%) had VATS (Figure 1).

Although a caliper width was included in the matching process, we were able to match every VATS patient to two OT patients. The matched sample consisted of 294 VATS and 588 OT patients. The characteristics with group differences before and after matching are shown in Table 1. Matching achieved a good balance with SMDs < 0.1 for all variables. All further results are reported for the matched sample.

Survival

69.2% of OT patients and 73.8% of VATS patients survived the 3-year observation period. This corresponds to 188 and 77 events respectively. The risk of dying was 19% lower in the VATS group (HR:0.81, CI:0.62;1.06). Figure 2 shows differences in the Kaplan-Meier curves in both groups.

Costs

Over the 3-year observation period, lung cancer-related mean costs amounted to €20,828 for the VATS group and €23,723 for the OT group. The resulting difference of €2,895 was statistically significant ($p=0.028$). The cost differences are shown in Figure 3. Costs for

rehabilitation made up only a small part of the total costs, and we found no significant differences between the groups. Mean costs for hospitalizations were €1,281 ($p=0.19$) and mean costs for drug prescriptions were €1,141 ($p=0.06$) lower in VATS patients. Costs of outpatient physician care were significantly lower (–€464 ($p=0.01$)) in VATS patients. Costs of the hospital stay for lobectomy were similar in VATS (€11,921) and OT (€12,281) patients, with a difference of only €361 ($p=0.573$). The results of the univariable GLM gamma regression are presented in Table 2.

Length of stay

After exclusion of 24 patients who died during the hospital stay with lobectomy 570 OT patients (96.9%) and 288 VATS patients (98.0%) were included in the analysis of post-operative LOS. Post-operative LOS in VATS patients (11.7 days) was 2.1 days shorter than in OT patients (13.8 days). The median post-operative length of stay was 11 days for OT and 9 days for VATS patients ($p<0.001$).

Sensitivity analysis

A total of 217 VATS patients survived the 3-year follow-up period and were matched with 434 OT patients. The variables used for PSM were well balanced after matching with all SMDs < 0.1. Lung cancer-related costs were significantly lower in the VATS group (–€2628, $p=0.050$) and the costs of the hospital stay with lobectomy did not differ (–€204, $p=0.614$).

226 **Table 1:** Patient characteristics of matched and unmatched population

		Matched		Unmatched	
	VATS (n=294)	OT (n=588)	SMD	OT (n=1465)	SMD
Mean age (SD)	66.8 (8.7)	67.18 (9.1)	0.040	67.01 (9.2)	0.020
Female (%)	119 (40.5)	241 (41.0)	0.010	450 (30.7)	0.205
Metastasis			0.029		0.349
None (%)	230 (78.2)	453 (77.0)		928 (63.3)	
Lymph nodes (%)	29 (9.9)	61 (10.4)		299 (20.4)	
Other (%)	35 (11.9)	74 (12.6)		238 (16.2)	
Median Charlson Index [Q1, Q3]	2.0 [1.0, 4.8]	2.0 [1.0, 4.0]	0.009	2.0 [1.0, 4.0]	0.002
Care level (%)	16 (5.4)	38 (6.5)	0.043	123 (8.4)	0.117
Nursing home (%)	0 (0.0)	0 (0.0)	<0.001	11 (0.8)	0.123
Neoadjuvant chemotherapy (%)	16 (5.4)	32 (5.4)	<0.001	123 (8.4)	0.117
Neoadjuvant radiotherapy (%)	0 (0.0)	0 (0.0)	<0.001	22 (1.5)	0.175
Median number of lobectomies per hospital [Q1, Q3]	5.0 [2.0, 13.0]	4.0 [2.0, 12.0]	0.041	4.0 [2.0, 12.0]	0.064
Median number of days between admission and lobectomy [Q1, Q3]	1.0 [1.0, 5.0]	2.0 [1.0, 4.0]	0.022	1.0 [1.0, 4.0]	0.002
Residential area			0.059		0.072
Unknown (%)	2 (0.7)	6 (1.0)		10 (0.7)	
Major city (%)	85 (28.9)	176 (29.9)		399 (27.2)	
Urban districts (%)	110 (37.4)	207 (35.2)		526 (35.9)	
Rural districts (%)	49 (16.7)	98 (16.7)		257 (17.5)	
Remote rural districts (%)	48 (16.3)	101 (17.2)		273 (18.6)	

SD: Standard deviation; Q: Quartile; SMD: Standardized mean difference; VATS: Video-assisted thoracoscopic surgery; OT: Open thoracotomy

Table 2: Group differences in lung cancer-related costs and costs of the hospital stay with lobectomy in the matched population

Matched population			
	VATS β	Difference 95% CI	p-value
Lung cancer-related costs (€)	- 2895	[-5219; -237]	0.028
Costs of the hospital stay with lobectomy (€)	-361	[-1473 ; 860]	0.573

CI: Confidence interval; VATS: Video-assisted thoracoscopic surgery

6. Discussion

The aim of this study was to evaluate possible differences between VATS and OT with regard to 3-year survival, costs of the hospital stay with lobectomy, 3-year lung cancer-related costs and LOS after lobectomy. To our knowledge, this is the first claims data study comparing VATS and OT in Germany.

In our study we did not find a significant difference between VATS and OT regarding overall survival, even though the risk of dying was 19% lower in VATS patients. However, when interpreting this result one has to consider that information on TNM stage was not available in the dataset. Previous publications in this regard are inconsistent. Taioli et al. [17] performed a meta-analysis in 2013 including 20 studies from 1990 to 2011. They reported a long-term survival benefit for patients undergoing VATS lobectomy in comparison with OT. Cai et al. [18] reported similar results in their meta-analysis from 2013, where they included nine studies focusing on stage I non-small cell lung cancer (NSCLC). In contrast, a recent meta-analysis from Hamaji et al. [6] from 2017, including 11 studies, reported no significant differences in long-term survival between VATS and OT in patients with early-stage NSCLC. Additionally, Hamaji et al. looked at seven other meta-analyses, including the studies of Taioli et al. and Cai et al., and concluded that all meta-analyses reported suboptimal effect measures and some of

them included studies that should have been ineligible. After removing the ineligible studies, 16 of the 17 remaining original studies were not significant. However, one has to consider that, in our study, 850 events would have been required to detect a 4.5% difference (as observed within our study) with a power of 80% at an alpha-level of 5%. Therefore, most studies on survival – including ours – were apparently too small to detect statistically meaningful differences. Thus, here, clinical relevance might be a more helpful decision criterion. Our Kaplan-Meier plot suggests a survival benefit for VATS soon after surgery, which continues over the whole observation period. Moreover, according to the German Institute for Quality and Efficiency in Health Care (IQWiG), interventions with a HR below 0.85 have an added value. Our study had a HR of 0.81.

When comparing VATS with OT regarding costs, our results show that the costs were lower for patients undergoing VATS. However, these differences were significant for lung cancer-related costs, but not for the costs of the hospital stay with lobectomy.

There are only a few studies investigating cost differences between VATS and OT beyond the hospital stay with lobectomy. Farjah et al. analysed claims data in the United States comparing inpatient, outpatient and pharmacy costs up to 90 days after lobectomy with data from 2007 to 2011 [19]. Costs for VATS patients were reported to be significantly lower. A prolonged LOS after lobectomy was named as the main reason for the cost differences between the groups. In our study we did not find significant differences in the costs of the hospital stay with lobectomy. Therefore cost differences in lung cancer-related costs cannot be explained by prolonged LOS. In another claims data analysis from the United States with data from 2010, health care expenditures and drug expenditures were compared for 90 days and 365 days after lobectomy [20]. No significant group differences were found in health care expenditures in the 90 and 365 days after lobectomy. Only 90 day drug expenditures were significantly different with lower costs for the VATS groups. To our knowledge, there are no studies reporting 3-year cost differences between VATS and OT comparable with our results. The differences in cancer-related costs were mainly driven by higher costs for OT patients in inpatient care, drug prescriptions and outpatient physician care. An explanation for this could

be that more patients in the OT group received adjuvant therapy after the resection, causing higher expenditures for chemotherapy and more hospitalizations. However, as we do not have information about the TNM stage of the patients, we cannot infer whether these differences in adjuvant therapy resulted from the resection method or different tumour sizes. Therefore, the differences have to be interpreted carefully.

Most previous studies, investigating differences between VATS and OT regarding costs of hospital stay with lobectomy adapt the hospitals' point of view. These studies report varying results, with some studies showing that the costs of the hospital stay are significantly lower for VATS patients [21, 22], comparable [23] or even higher [24, 25]. These inconclusive findings might arise from study-driven and framework related differences, e.g. no confounder adjustment or small sample sizes. Additionally, it is not possible to draw a conclusion concerning the costs when comparing VATS and OT in an international context. Differences between countries, e.g. Taiwan, Turkey, Poland and Germany [24-26] are too big because of different costs for materials and hospital staff. In our study costs of the hospital stay did not differ significantly. The payer perspective of the study can probably explain the main reason for this. In Germany, VATS and OT are assigned to the same DRG; therefore, the amount of reimbursement paid by the health insurance company is the same for VATS and OT. So, the comparable costs for the hospital stay with lobectomy were not unexpected. Additionally, a supplementary payment to the DRG is only indicated if the patient has severe complications or the LOS is beyond 21 days after admission. Therefore, even if the mean LOS was 2.1 days shorter in patients undergoing VATS in our study, this has only a small impact on the costs of the hospital stay reimbursed by the health insurance fund. Here, adjustments in the current DRG system could change the preference for either procedure from a payer perspective in the long run.

However, up to now, it remains unclear which approach is more beneficial for the hospitals in Germany, as it is not clear whether a shorter post-operative LOS or other advantages that VATS possibly entails can compensate for the higher costs of materials, e.g. staplers.

Post-operative LOS is an outcome frequently studied when comparing VATS and OT. In our study, post-operative LOS was significantly shorter in patients undergoing VATS. Our results are in line with several studies comparing post-operative LOS between VATS and OT. Two published meta-analyses support these findings [3, 27] as well as a recently published randomized controlled trial (RCT) [4]. Compared with other studies, post-operative LOS was longer in our analysis. This can be explained as an artefact of the German health care system which is characterized by extended hospital stays. According to the OECD, Germany was the country with the fourth highest average LOS for hospitalizations in 2013 [28]. For example, the average LOS was 2.3 days higher in Germany compared to the United States (7.7 days vs. 5.4 days). Another reason might be the source of the data. Whereas most studies are performed in single institutions, our data cover many hospitals throughout Germany. Single institution studies are mostly performed in specialized hospitals, which might perform more surgeries. In a claims data study in the United States, a lower LOS was reported in high-volume hospitals [29]. When comparing the median post-operative LOS with claims data studies, the difference between the reported post-operative LOS compared with our study becomes smaller. For instance, the median post-operative LOS in a study from the European Society of Thoracic Surgeons database reports a median LOS of 6 days for VATS and 8 days for OT patients [30].

Our sensitivity analysis, including only patients who survived for at least 3 years, resulted in a significant, but lower difference between the two groups concerning lung cancer-related costs. Even though the overall survival did not differ significantly between the groups, we observed a difference in survival rates (69.2% OT vs. 73.8% VATS). However, this does not explain the higher lung cancer-related costs in the OT group. As in the main cost analysis, the missing information on TNM stage has to be taken into account and differences have to be interpreted carefully.

When interpreting the results of this study, some caveats have to be considered. First, unmeasured confounding is possible, as PSM just balances for measured confounding. Possible confounders are behavioural risk factors, TNM-stage, tumour histology and severity

of comorbidities. However, by including metastasis status, neoadjuvant therapy and comorbidities at baseline, we tried to address this issue as well as possible. Nevertheless, this careful adaptation cannot fully reflect the missing clinical data. Another limitation is that we have no information about the conversion from VATS to OT. It may be possible that patients initially indicated for VATS received an OT. In survival analysis we just had information about all-cause mortality. It would be more appropriate to analyse survival for lung cancer-related death when comparing VATS and OT. Assessment of lung cancer-related costs might be vulnerable to distortions, e.g. if patients had multiple tumours we would overestimate the lung cancer-related costs.

In contrast to these drawbacks, our study has the advantage of providing insights into real world health care provision across a population-representative cohort of lung cancer patients in Germany. In addition, this is the first large multicentre study in Germany comparing VATS and OT across hospitals with different degrees of specialization and one of a few looking into follow-up care after lobectomy with a time horizon of several years. Unlike most other studies we had complete patient-level information beyond the hospital stay for a 3-year follow-up period.

Conclusion

Our results suggest that, at least from a payer perspective, the performance of VATS is beneficial, as VATS shows advantages in post-operative LOS and follow-up costs of care. Although we did not find significant differences in survival, we believe that differences displayed in the survival curves could indicate survival benefits. Furthermore, for a more comprehensive evaluation of the benefits of VATS from a societal point of view, further aspects such as patient-reported outcomes and provider-related standby costs are required. The limitations of studies such as ours have to be kept in mind, and higher levels of evidence are needed to determine causal relationships.

Conflict of interest statement

359 none declared.

360

361 **Acknowledgements**

362 We thank Jürgen Bernhard Adler and Christian Günster (WIdO) for providing their data for
363 our analysis.

364




Figure 1: Participant flow of study population

VATS: Video-assisted thoracoscopic surgery; OT: Open thoracotomy;
PSM: Propensity Score Matching




Figure 2: Kaplan-Meier survival curves for group comparison of VATS versus OT with 95% confidence bands

OT: Open thoracotomy; VATS: Video-assisted thoracoscopic surgery




Figure 3: Lung cancer-related costs in cost categories and among resection groups

OT: Open thoracotomy; VATS: Video-assisted thoracoscopic surgery

7. References

- [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;**68**:394-424.
- [2] Dziedzic D, Orlowski T. *The Role of VATS in Lung Cancer Surgery: Current Status and Prospects for Development*. *Minim Invasive Surg* 2015;**2015**:938430.
- [3] Cao C, Manganas C, Ang SC, Peeceeyen S, Yan TD. *Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity score-matched patients*. *Interact Cardiovasc Thorac Surg* 2013;**16**:244-9.
- [4] Bendixen M, Jorgensen OD, Kronborg C, Andersen C, Licht PB. *Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial*. *Lancet Oncol* 2016;**17**:836-44.
- [5] Yan TD, Black D, Bannon PG, McCaughan BC. *Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer*. *J Clin Oncol* 2009;**27**:2553-62.
- [6] Hamaji M, Lee HS, Kawaguchi A, Burt BM. *Overall Survival Following Thoracoscopic vs Open Lobectomy for Early-stage Non-small Cell Lung Cancer: A Meta-analysis*. *Semin Thorac Cardiovasc Surg* 2017;**29**:104-12.
- [7] Swanson SJ, Meyers BF, Gunnarsson CL, Moore M, Howington JA, Maddaus MA *et al*. *Video-assisted thoracoscopic lobectomy is less costly and morbid than open lobectomy: a retrospective multiinstitutional database analysis*. *Ann Thorac Surg* 2012;**93**:1027-32.
- [8] Gopaldas RR, Bakaeen FG, Dao TK, Walsh GL, Swisher SG, Chu D. *Video-assisted thoracoscopic versus open thoracotomy lobectomy in a cohort of 13,619 patients*. *Ann Thorac Surg* 2010;**89**:1563-70.
- [9] German Federal Ministry of Health. *Gesetzliche Krankenversicherung - Mitglieder, mitversicherte Angehörige und Krankenstand - Jahresdurchschnitt 2013*. <https://www.bundesgesundheitsministerium.de/themen/krankenversicherung/zahlen-und-fakten-zur-krankenversicherung/mitglieder-und-versicherte.html> (18.06.2018 date last accessed).
- [10] Federal Institute for Research on Building Urban Affairs and Spatial Development. *Laufende Raumbbeobachtung - Raumabgrenzungen*. <https://www.bbsr.bund.de/BBSR/DE/Raumbbeobachtung/Raumabgrenzungen/Kreistypen4/kreistypen.html> (02.07.2018 date last accessed).
- [11] Austin PC. *Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies*. *Pharm Stat* 2011;**10**:150-61.
- [12] Austin PC. *An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies*. *Multivariate Behav Res* 2011;**46**:399-424.
- [13] Austin PC. *Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score*. *Am J Epidemiol* 2010;**172**:1092-7.
- [14] Stuart EA. *Matching methods for causal inference: A review and a look forward*. *Stat Sci* 2010;**25**:1–21.
- [15] Manning WG, Basu A, Mullahy J. *Generalized modeling approaches to risk adjustment of skewed outcomes data*. *J Health Econ* 2005;**24**:465-88.
- [16] Malehi AS, Pourmotahari F, Angali KA. *Statistical models for the analysis of skewed healthcare cost data: a simulation study*. *Health Econ Rev* 2015;**5**:11.
- [17] Taioli E, Lee DS, Lesser M, Flores R. *Long-term survival in video-assisted thoracoscopic lobectomy vs open lobectomy in lung-cancer patients: a meta-analysis*. *Eur J Cardiothorac Surg* 2013;**44**:591-7.
- [18] Cai YX, Fu XN, Xu QZ, Sun W, Zhang N. *Thoracoscopic lobectomy versus open lobectomy in stage I non-small cell lung cancer: a meta-analysis*. *PLoS One* 2013;**8**:e82366.

- [19] Farjah F, Backhus LM, Varghese TK, Mulligan MS, Cheng AM, Alfonso-Cristancho R *et al.* *Ninety-day costs of video-assisted thoracic surgery versus open lobectomy for lung cancer.* Ann Thorac Surg 2014;**98**:191-6.
- [20] Watson TJ, Qiu J. *The Impact of Thoracoscopic Surgery on Payment and Health Care Utilization After Lung Resection.* Ann Thorac Surg 2016;**101**:1271-9; discussion 979-80.
- [21] Casali G, Walker WS. *Video-assisted thoracic surgery lobectomy: can we afford it?* Eur J Cardiothorac Surg 2009;**35**:423-8.
- [22] Ramos R, Masuet C, Gossot D. *Lobectomy for early-stage lung carcinoma: a cost analysis of full thoracoscopy versus posterolateral thoracotomy.* Surg Endosc 2012;**26**:431-7.
- [23] Cho S, Do YW, Lee EB. *Comparison of costs for video-assisted thoracic surgery lobectomy and open lobectomy for non-small cell lung cancer.* Surg Endosc 2011;**25**:1054-61.
- [24] Alpay L, Lacin T, Teker D, Okur E, Baysungur V, Kanbur S *et al.* *A comparative cost analysis study of lobectomy performed via video-assisted thoracic surgery versus thoracotomy in Turkey.* Wideochir Inne Tech Maloinwazyjne 2014;**9**:409-14.
- [25] Piwkowski C, Gabryel P, Galecki B, Roszak M, Dyszkiewicz W. *High costs as a slow down factor of thoracoscopic lobectomy development in Poland - an institutional experience.* Wideochir Inne Tech Maloinwazyjne 2013;**8**:334-41.
- [26] Wang BY, Huang JY, Ko JL, Lin CH, Zhou YH, Huang CL *et al.* *A Population-Based Cost Analysis of Thoracoscopic Versus Open Lobectomy in Primary Lung Cancer.* Ann Surg Oncol 2016;**23**:2094-8.
- [27] Chen FF, Zhang D, Wang YL, Xiong B. *Video-assisted thoracoscopic surgery lobectomy versus open lobectomy in patients with clinical stage non-small cell lung cancer: a meta-analysis.* Eur J Surg Oncol 2013;**39**:957-63.
- [28] OECD. *Length of hospital stay.* <https://data.oecd.org/healthcare/length-of-hospital-stay.htm> (20.07.2018 date last accessed).
- [29] Park HS, Detterbeck FC, Boffa DJ, Kim AW. *Impact of hospital volume of thoracoscopic lobectomy on primary lung cancer outcomes.* Ann Thorac Surg 2012;**93**:372-9.
- [30] Falcoz PE, Puyraveau M, Thomas PA, Decaluwe H, Hurtgen M, Petersen RH *et al.* *Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database.* Eur J Cardiothorac Surg 2016;**49**:602-9.